Oligometastatic Disease in Pancreatic Cancer - How to Proceed?

Overview

Journal Visc Med

Date 2017 Jun 15

PMID 28612015

Citations 17

Authors

Bernhard W Renz

Stefan Boeck

Falk Roeder

Christoph Trumm

Volker Heinemann

Jens Werner

Affiliations

Soon will be listed here.

Abstract

Background: Pancreatic cancer is a highly aggressive malignancy and will become the second leading cause of cancer-related death in the USA and also in Germany by 2030. Furthermore, the majority of patients with pancreatic ductal adenocarcinoma (PDAC) will present with distant metastases, limiting surgical management in this population as there is little evidence available to support surgical or ablative treatment options for advanced-stage disease. However, highly selected patients suffering from synchronous and metachronous oligometastatic PDAC may potentially benefit from a surgical resection with an acceptable morbidity.

Methods: This review summarizes and discusses the current literature on the management of oligometastatic disease regarding PDAC, focusing on para-aortic lymph nodes as well as isolated hepatic and pulmonary metastases.

Results And Conclusion: In order to further investigate the feasibility and efficacy of such an approach, a prospective multicenter trial, in which survival and quality of life after metastatic resection and systemic chemotherapy is evaluated, has to be initiated. Additionally, local and locoregional ablation techniques or stereotactic body radiation therapy as therapeutic options for isolated metastases in PDAC need further research in order to determine their significance and benefit.

Citing Articles

Study protocol of the METAPANC trial - intensified treatment in patients with local operable but oligometastatic pancreatic cancer - multimodal surgical treatment versus chemotherapy alone: a randomized controlled trial.

Ghadimi M, Pelzer U, Besselink M, Siveke J, Telgmann R, Braren R BMC Cancer. 2025; 25(1):208.

PMID: 39915735 PMC: 11800597. DOI: 10.1186/s12885-025-13573-7.

Characterization of an oligometastatic state in patients with metastatic pancreatic adenocarcinoma undergoing systemic chemotherapy.

de Ortiz de Choudens S, Visotcky A, Banerjee A, Aldakkak M, Tsai S, Evans D Cancer Med. 2023; 13(1):e6582.

PMID: 38140796 PMC: 10807686. DOI: 10.1002/cam4.6582.

Diagnostic Bioliquid Markers for Pancreatic Cancer: What We Have vs. What We Need.

Liou G, Byrd C Cancers (Basel). 2023; 15(9).

PMID: 37173913 PMC: 10177101. DOI: 10.3390/cancers15092446.

A multi-omics approach identifies pancreatic cancer cell extracellular vesicles as mediators of the unfolded protein response in normal pancreatic epithelial cells.

Hinzman C, Singh B, Bansal S, Li Y, Iliuk A, Girgis M J Extracell Vesicles. 2022; 11(6):e12232.

PMID: 35656858 PMC: 9164146. DOI: 10.1002/jev2.12232.

Serum Exosomal miRNA-1226 as Potential Biomarker of Pancreatic Ductal Adenocarcinoma.

Wang C, Wang J, Cui W, Liu Y, Zhou H, Wang Y Onco Targets Ther. 2021; 14:1441-1451.

PMID: 33664577 PMC: 7924134. DOI: 10.2147/OTT.S296816.

References

Kruger S, Haas M, Burger P, Ormanns S, Modest D, Westphalen C . Isolated pulmonary metastases define a favorable subgroup in metastatic pancreatic cancer. Pancreatology. 2016; 16(4):593-8. DOI: 10.1016/j.pan.2016.03.016. View

Lemke J, Scheele J, Kapapa T, Wirtz C, Henne-Bruns D, Kornmann M . Brain metastasis in pancreatic cancer. Int J Mol Sci. 2013; 14(2):4163-73. PMC: 3588092. DOI: 10.3390/ijms14024163. View

Kolokythas A, Miloro M, Olsson A, Miloro M . Metastatic pancreatic adenocarcinoma to the mandibular condyle: a rare clinical presentation. J Oral Maxillofac Surg. 2013; 72(1):83-8. DOI: 10.1016/j.joms.2013.06.207. View

diSibio G, French S . Metastatic patterns of cancers: results from a large autopsy study. Arch Pathol Lab Med. 2008; 132(6):931-9. DOI: 10.5858/2008-132-931-MPOCRF. View

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K . Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297(3):267-77. DOI: 10.1001/jama.297.3.267. View

Mao C, Domenico D, Kim K, Hanson D, Howard J . Observations on the developmental patterns and the consequences of pancreatic exocrine adenocarcinoma. Findings of 154 autopsies. Arch Surg. 1995; 130(2):125-34. DOI: 10.1001/archsurg.1995.01430020015001. View

Veereman G, Robays J, Verleye L, Leroy R, Rolfo C, Van Cutsem E . Pooled analysis of the surgical treatment for colorectal cancer liver metastases. Crit Rev Oncol Hematol. 2015; 94(1):122-35. DOI: 10.1016/j.critrevonc.2014.12.004. View

Vigano L, Russolillo N, Ferrero A, De Rosa G, Ferreri E, Forchino F . Resection of liver metastases from colorectal mucinous adenocarcinoma: is this a different disease? Results of a case-control study. Ann Surg. 2014; 260(5):878-84. DOI: 10.1097/SLA.0000000000000981. View

Park J, Kim Y, Kim J, Chang H, Kim T, Kim S . Radiofrequency ablation of liver metastasis in patients with locally controlled pancreatic ductal adenocarcinoma. J Vasc Interv Radiol. 2012; 23(5):635-41. DOI: 10.1016/j.jvir.2012.01.080. View

10.

Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A . Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2016; 43(2):358-363. DOI: 10.1016/j.ejso.2016.10.023. View

11.

Conroy T, Desseigne F, Ychou M, Bouche O, Guimbaud R, Becouarn Y . FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011; 364(19):1817-25. DOI: 10.1056/NEJMoa1011923. View

12.

Chen J, Tang Z, Dong X, Gao S, Fang H, Wu D . Radiofrequency ablation for liver metastasis from gastric cancer. Eur J Surg Oncol. 2013; 39(7):701-6. DOI: 10.1016/j.ejso.2013.03.023. View

13.

Michalski C, Erkan M, Huser N, Muller M, Hartel M, Friess H . Resection of primary pancreatic cancer and liver metastasis: a systematic review. Dig Surg. 2009; 25(6):473-80. DOI: 10.1159/000184739. View

14.

Klempnauer J, Ridder G, Bektas H, Pichlmayr R . Extended resections of ductal pancreatic cancer--impact on operative risk and prognosis. Oncology. 1996; 53(1):47-53. DOI: 10.1159/000227534. View

15.

Sofocleous C, Sideras P, Petre E . "How we do it" - a practical approach to hepatic metastases ablation techniques. Tech Vasc Interv Radiol. 2013; 16(4):219-29. DOI: 10.1053/j.tvir.2013.08.005. View

16.

Ripley R, Kemp C, Davis J, Langan R, Royal R, Libutti S . Liver resection and ablation for metastatic adrenocortical carcinoma. Ann Surg Oncol. 2011; 18(7):1972-9. PMC: 3272672. DOI: 10.1245/s10434-011-1564-z. View

17.

Rao R, Sadashiv S, Goday S, Monga D . An extremely rare case of pancreatic cancer presenting with leptomeningeal carcinomatosis and synchronous intraparenchymal brain metastasis. Gastrointest Cancer Res. 2013; 6(3):90-2. PMC: 3737512. View

18.

OGrady H, Conlon K . Pancreatic neuroendocrine tumours. Eur J Surg Oncol. 2007; 34(3):324-32. DOI: 10.1016/j.ejso.2007.07.209. View

19.

Nakajima M, Ueno T, Suzuki N, Matsui H, Shindo Y, Sakamoto K . Novel Indications for Surgical Resection of Metachronous Lung Metastases From Pancreatic Cancer After Curative Resection. J Clin Gastroenterol. 2016; 51(5):e34-e38. DOI: 10.1097/MCG.0000000000000551. View

20.

Paiella S, Sandini M, Gianotti L, Butturini G, Salvia R, Bassi C . The prognostic impact of para-aortic lymph node metastasis in pancreatic cancer: A systematic review and meta-analysis. Eur J Surg Oncol. 2016; 42(5):616-24. DOI: 10.1016/j.ejso.2016.02.003. View